Summary: Clear cell renal cell carcinoma (ccRCC) is characterized by loss of the von Hippel–Lindau tumor suppressor gene (VHL), and the functional tumorigenic consequences of this loss have been used to develop therapies for advanced ccRCC, such as targeting activation of the HIF pathway. Yao and colleagues elucidate how VHL loss contributes to chromatin alteration at both gene promoters and enhancers/superenhancers, in both an HIF-dependent as well as independent manner, and how this may provide additional targets for therapeutic intervention in advanced ccRCC. Cancer Discov; 7(11); 1221–3. ©2017 AACR.

See related article by Yao et al., p. 1284.

简介：透明细胞肾细胞癌（ccRCC）的特征是von Hippel–Lindau肿瘤抑制基因（VHL）缺失，这种缺失的功能致瘤作用已用于开发晚期ccRCC的疗法，例如靶向激活ccRCC。 HIF途径。Yao和同事阐明了VHL丢失如何以HIF依赖和独立的方式促进基因启动子和增强子/超增强子上的染色质改变，以及如何为晚期ccRCC的治疗干预提供其他靶点。巨蟹座Discov; 7（11）；1221–3。©2017 AACR。

参见Yao等人的相关文章，第2页。1284年。